Research programme: antibacterials - Merck
Alternative Names: CB-182,462Latest Information Update: 25 Sep 2019
At a glance
- Originator Cubist Pharmaceuticals
- Developer Merck & Co
- Class Lipopeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections; Gram-positive infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-positive-infections in USA
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co